๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Comparison of pramipexole, fluoxetine, and placebo in patients with major depression

โœ Scribed by Mark H. Corrigan; Angelita Q. Denahan; C. Eugene Wright; Rhonda J. Ragual; Dwight L. Evans


Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
195 KB
Volume
11
Category
Article
ISSN
1091-4269

No coin nor oath required. For personal study only.

โœฆ Synopsis


Pramipexole, a dopamine D 2 receptor agonist, was tested in 174 patients with major depression, with or without melancholia and without psychotic features. Three daily dose levels (0.375 mg, 1.0 mg, and 5.0 mg) were compared to fluoxetine (Prozac) at 20 mg and placebo in a randomized, double-blind, parallel-group study. After a 1 week placebo run-in period, patients were treated for 8 11:58-65, 2000.

weeks, had a post-study follow-up (week 9), and were evaluated primarily with the Hamilton Psychiatric Rating Scale for Depression (HAM-D), the Montgomery-Asberg Depression Rating Scale (MADRS), and the Clinician's Global Impressions-Severity of Illness scale (CGI-SI). All patients who received one dose of study medication were included in the observed-case analysis (no missing data were replaced). Results indicated that by endpoint (week 8), patients receiving pramipexole at the 1.0 mg per day dose had significant improvement over baseline compared to the placebo group by measure of the HAM-D, MADRS, and CGI-SI. Significant improvement in this dose group was seen at other timepoints as well. The most obvious improvement was seen in the pramipexole 5.0 mg group, although a substantial dropout rate for this group precluded statistical tests vs. placebo late in the study. Patients taking fluoxetine also showed significant improvements at endpoint on the MADRS and earlier in the study on the HAM-D. No new or unusual safety concerns were generated during this study. Pramipexole helped safely alleviate the symptoms of depression at 1.0 mg per day and especially in those patients who could tolerate the escalation to 5 mg per day. Depression and Anxiety


๐Ÿ“œ SIMILAR VOLUMES


Study of haemostasis in depressive patie
โœ Pascale Lainรฉ-Cessac; Iran Shoaay; Jean-Bernard Garre; Valerie Glaud; Alain Turc ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 103 KB ๐Ÿ‘ 2 views

The object of this study was to investigate a possible pharmacological eect of ยฏuoxetine on haemostatic function, with special attention on primary haemostasis, in order to explain haemorrhagic complications reported in some treated, depressed patients. The haemostatic function of depressive patient

Double-blind comparison of citalopram an
โœ Joseph Mendels; Ari Kiev; Louis F. Fabre ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 92 KB ๐Ÿ‘ 2 views

## This multicenter study compared the efficacy and safety of citalopram and placebo in a population of moderately to severely depressed patients with melancholia. This randomized, double-blind, parallel-group study compared citalopram (flexible dose; 20-80 mg/day) with placebo in 180 psychiatric ou

Effectiveness of fluoxetine and doxepin
โœ Paul Sandor; Brian Baker; Jane Irvine; Paul Dorian; D. McKessok; S. Mendlowitz ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 50 KB ๐Ÿ‘ 2 views

It has been suggested that serotonin reuptake inhibitors (SSRIs) may be less effective than tricyclic antidepressants (TCAs) in treatment of melancholic depression. We treated 36 depressed ambulatory patients with doxepin or fluoxetine in a double-blind, randomized 6-week trial with placebo run-in.

Antibodies against serotonin and ganglio
โœ W. Samborski; A. Sluzewska; J. K. Lacki; M. Sobieska; R. Klein; S. Mackiewicz ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 75 KB ๐Ÿ‘ 1 views

Antibodies against serotonin and gangliosides in patients with ยฎbromyalgia and major depression The ยฎbromyalgia syndrome (FMS) is a nonarticular disorder associated with disturbances in serotonin (5-HT) metabolism Samborski et al., 1996a,b). Moreover the psychological proยฎles of these patients rev

A double-blind, multicenter trial compar
โœ Lesley M. Arnold; Yili Lu; Leslie J. Crofford; Madelaine Wohlreich; Michael J. D ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 115 KB

## Abstract ## Objective To assess the efficacy and safety of duloxetine, a serotonin and norepinephrine reuptake inhibitor, in subjects with primary fibromyalgia, with or without current major depressive disorder. ## Methods This study was a randomized, doubleโ€blind, placeboโ€controlled trial co